Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification
Case 1: A 67-year-old Asian female was diagnosed with locally advanced high-grade salivary duct carcinoma in June 2011. Molecular analysis revealed human epidermal growth factor receptor 2 (HER-2) amplification. She received adjuvant therapy with carboplatin/paclitaxel/ trastuzumab and maintenance o...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2016-06-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/445827 |
id |
doaj-bbe7978b198647deab84f52aeb8c7149 |
---|---|
record_format |
Article |
spelling |
doaj-bbe7978b198647deab84f52aeb8c71492020-11-24T23:01:56ZengKarger PublishersCase Reports in Oncology1662-65752016-06-019229830410.1159/000445827445827Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 AmplificationDaniel Sanghoon ShinTimothy SherryMichael E. KallenSteven WongAlexandra DrakakiCase 1: A 67-year-old Asian female was diagnosed with locally advanced high-grade salivary duct carcinoma in June 2011. Molecular analysis revealed human epidermal growth factor receptor 2 (HER-2) amplification. She received adjuvant therapy with carboplatin/paclitaxel/ trastuzumab and maintenance of trastuzumab. Upon disease progression, trastuzumab could not be continued due to lack of financial coverage. Instead, she was treated with compassionate use of lapatinib from April 2013 and standard 5-fluorouracil. Her disease ultimately progressed and she expired later in 2013. Case 2: A 68-year-old Asian male was diagnosed with extramammary Paget's disease of the scrotum with HER-2 amplification in May 2011. He received 6 cycles of adjuvant trastuzumab/docetaxel/carboplatin followed by maintenance trastuzumab, which was changed to compassionate use of lapatinib as his insurance did not cover further administration of trastuzumab. He showed clinical benefits from single-agent lapatinib and a combination of lapatinib/capecitabine upon progression to the single-agent lapatinib. Ultimately, he was started on ado-trastuzumab emtansine, which was approved at that time by the FDA for HER-2-positive breast cancer progressed on trastuzumab. He is having clinical and radiographic complete response based on current imaging and normalization of his tumor markers. Conclusion: HER-2-targeted therapy should be considered for tumors with HER-2 amplification. In our case series, we would like to emphasize this approach in other rare histologies. Specifically, our patient with extramammary Paget's disease of the scrotum represents the first reported case of a non-breast, non-gastric tumor with HER-2 overexpression with complete clinical and radiographic response to HER-2-targeted therapy.http://www.karger.com/Article/FullText/445827Human epidermal growth factor receptor 2Extramammary Paget’s disease of the scrotumSalivary duct carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Daniel Sanghoon Shin Timothy Sherry Michael E. Kallen Steven Wong Alexandra Drakaki |
spellingShingle |
Daniel Sanghoon Shin Timothy Sherry Michael E. Kallen Steven Wong Alexandra Drakaki Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification Case Reports in Oncology Human epidermal growth factor receptor 2 Extramammary Paget’s disease of the scrotum Salivary duct carcinoma |
author_facet |
Daniel Sanghoon Shin Timothy Sherry Michael E. Kallen Steven Wong Alexandra Drakaki |
author_sort |
Daniel Sanghoon Shin |
title |
Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification |
title_short |
Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification |
title_full |
Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification |
title_fullStr |
Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification |
title_full_unstemmed |
Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification |
title_sort |
human epidermal growth factor receptor 2 (her-2/neu)-directed therapy for rare metastatic epithelial tumors with her-2 amplification |
publisher |
Karger Publishers |
series |
Case Reports in Oncology |
issn |
1662-6575 |
publishDate |
2016-06-01 |
description |
Case 1: A 67-year-old Asian female was diagnosed with locally advanced high-grade salivary duct carcinoma in June 2011. Molecular analysis revealed human epidermal growth factor receptor 2 (HER-2) amplification. She received adjuvant therapy with carboplatin/paclitaxel/ trastuzumab and maintenance of trastuzumab. Upon disease progression, trastuzumab could not be continued due to lack of financial coverage. Instead, she was treated with compassionate use of lapatinib from April 2013 and standard 5-fluorouracil. Her disease ultimately progressed and she expired later in 2013. Case 2: A 68-year-old Asian male was diagnosed with extramammary Paget's disease of the scrotum with HER-2 amplification in May 2011. He received 6 cycles of adjuvant trastuzumab/docetaxel/carboplatin followed by maintenance trastuzumab, which was changed to compassionate use of lapatinib as his insurance did not cover further administration of trastuzumab. He showed clinical benefits from single-agent lapatinib and a combination of lapatinib/capecitabine upon progression to the single-agent lapatinib. Ultimately, he was started on ado-trastuzumab emtansine, which was approved at that time by the FDA for HER-2-positive breast cancer progressed on trastuzumab. He is having clinical and radiographic complete response based on current imaging and normalization of his tumor markers. Conclusion: HER-2-targeted therapy should be considered for tumors with HER-2 amplification. In our case series, we would like to emphasize this approach in other rare histologies. Specifically, our patient with extramammary Paget's disease of the scrotum represents the first reported case of a non-breast, non-gastric tumor with HER-2 overexpression with complete clinical and radiographic response to HER-2-targeted therapy. |
topic |
Human epidermal growth factor receptor 2 Extramammary Paget’s disease of the scrotum Salivary duct carcinoma |
url |
http://www.karger.com/Article/FullText/445827 |
work_keys_str_mv |
AT danielsanghoonshin humanepidermalgrowthfactorreceptor2her2neudirectedtherapyforraremetastaticepithelialtumorswithher2amplification AT timothysherry humanepidermalgrowthfactorreceptor2her2neudirectedtherapyforraremetastaticepithelialtumorswithher2amplification AT michaelekallen humanepidermalgrowthfactorreceptor2her2neudirectedtherapyforraremetastaticepithelialtumorswithher2amplification AT stevenwong humanepidermalgrowthfactorreceptor2her2neudirectedtherapyforraremetastaticepithelialtumorswithher2amplification AT alexandradrakaki humanepidermalgrowthfactorreceptor2her2neudirectedtherapyforraremetastaticepithelialtumorswithher2amplification |
_version_ |
1725638287012397056 |